<p>Apogee Therapeutics Inc.（纳斯达克代码：APGE - 获取免费报告）内部人士 Carl Dambkowski 于 12 月 4 日星期四出售了 10,900 股该公司的股票。股票以平均价格 75.00 美元出售，总价值为 817,500.00 美元。出售后，该内部人士直接持有 271,108 股公司股票，价值 20,333,100 美元。这笔交易代表了他们持股比例的 3.87% 的减少。此次出售在提交给证券交易委员会的文件中披露，该文件可通过 SEC 网站获取。</p>
<ul>
<li>2024 年 IPO 观察：哪些新股票将上市？</li>
</ul>
<p>Carl Dambkowski 最近还进行了以下交易：</p>
<ul>
<li>在 11 月 5 日星期三，Carl Dambkowski 出售了 10,785 股 Apogee Therapeutics 的股票。股票以平均价格 55.07 美元出售，总价值为 593,929.95 美元。</li>
<li>在 10 月 1 日星期三，Carl Dambkowski 出售了 5,110 股 Apogee Therapeutics 的股票。股票以平均价格 39.80 美元出售，总价值为 203,378.00 美元。</li>
</ul>
<p>获取 <strong>Apogee Therapeutics</strong> 的提醒：</p>
<h2>Apogee Therapeutics 价格表现</h2>
<p>Apogee Therapeutics 的股票在周五的交易时段上涨了 1.25 美元，达到 76.75 美元。该公司的交易量为 733,690 股，而其平均交易量为 715,559 股。Apogee Therapeutics Inc.的 52 周低点为 26.20 美元，52 周高点为 77.09 美元。该公司的市值为 52.4 亿美元，市盈率为-17.52，贝塔值为 1.41。该公司的 50 日移动平均线为 57.59 美元，200 日移动平均线为 45.43 美元。</p>
<p>Apogee Therapeutics（纳斯达克代码：APGE - 获取免费报告）最近于 11 月 10 日星期一发布了季度财报。该公司报告每股收益（EPS）为-1.11 美元，超出分析师一致预期的-1.14 美元，超出幅度为 0.03 美元。分析师预计 Apogee Therapeutics Inc.在当前年度的每股收益为-3.09 美元。</p>
<h2>机构投资者对 Apogee Therapeutics 的看法</h2>
<p>几家对冲基金和其他机构投资者最近调整了对该股票的持有。Nisa Investment Advisors LLC 在第二季度将其在 Apogee Therapeutics 的持股增加了 99.2%。Nisa Investment Advisors LLC 现在拥有 769 股该公司的股票，价值 33,000 美元，此前在此期间购买了 383 股。ANTIPODES PARTNERS Ltd 在第三季度将其在 Apogee Therapeutics 的持股增加了 41.2%。ANTIPODES PARTNERS Ltd 现在拥有 843 股该公司的股票，价值 33,000 美元，此前在上个季度购买了 246 股。Brooklyn Investment Group 在第一季度购买了 Apogee Therapeutics 的新头寸，价值约 42,000 美元。AlphaQuest LLC 在第一季度获得了 Apogee Therapeutics 的新头寸，价值约 43,000 美元。最后，Mirae Asset Global Investments Co. Ltd.在第二季度将其在 Apogee Therapeutics 的持股增加了 18.0%。Mirae Asset Global Investments Co. Ltd.现在拥有 1,779 股该公司的股票，价值 77,000 美元，此前在此期间购买了 272 股。机构投资者和对冲基金持有该公司 79.04% 的股票。</p>
<h2>华尔街分析师的看法</h2>
<p>APGE 最近成为几份研究报告的主题。BTIG Research 在 10 月 9 日星期四重新发布了 “买入” 评级，并对 Apogee Therapeutics 的股票设定了 115.00 美元的目标价。瑞穗证券在 10 月 21 日星期二开始对 Apogee Therapeutics 的股票进行覆盖。他们对该公司发布了 “跑赢大盘” 评级和 105.00 美元的目标价。加拿大皇家银行在 11 月 3 日星期一将 Apogee Therapeutics 的股票目标价从 60.00 美元提高至 70.00 美元，并给予该股票 “跑赢大盘” 评级。Wall Street Zen 在 11 月 15 日星期六将 Apogee Therapeutics 的股票评级从 “卖出” 上调至 “持有”。最后，Craig Hallum 在 11 月 3 日星期一开始对 Apogee Therapeutics 的股票进行覆盖。他们对该公司发布了 “买入” 评级和 109.00 美元的目标价。一位投资分析师对该股票给予了强烈买入评级，七位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 98.38 美元。</p>
<p><strong>查看我们对 APGE 的最新分析</strong></p>
<h2>Apogee Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Apogee Therapeutics, Inc.通过其子公司作为一家生物技术公司，开发用于治疗特应性皮炎（AD）、哮喘、慢性阻塞性肺病（COPD）及相关炎症和免疫学适应症的生物制剂。该公司主要开发 APG777，一种用于 AD 的皮下（SQ）延长半衰期单克隆抗体（mAb）；以及 APG808，一种用于 COPD 的 SQ 延长半衰期单克隆抗体。</p>
<h2>特色文章</h2>
<ul>
<li>我们更喜欢的五只股票比 Apogee Therapeutics 更好</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>Rocket Lab 的大反弹？分析师建议这次下跌是个机会</li>
<li>便士股票适合你的投资组合吗？</li>
<li>Meta 的 AI 时刻？新的 SAM 3 模型让华尔街变得乐观</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBHRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBHRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Apogee Therapeutics 吗？</h2>
<p>在你考虑 Apogee Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Apogee Therapeutics 并不在名单上。</p>
<p>虽然 Apogee Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

远地点企业

<p>Apogee Therapeutics 的内部人士 Carl Dambkowski 出售了 10,900 股，每股售价 75 美元，总计 817,500 美元。这笔交易使他的持股比例减少了 3.87%，目前他持有 271,108 股，价值 20,333,100 美元。该交易已在 SEC 文件中披露。还讨论了 Apogee 的股票表现和分析师评级，目前的平均评级为 “适度买入”，目标价格为 98.38 美元</p>

<p>Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 10,900 shares of the business's stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $75.00, for a total value of $817,500.00. Following the sale, the insider directly owned 271,108 shares in the company, valued at $20,333,100. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website.</p>
<div class="lb-trans"><p>Apogee Therapeutics Inc.（纳斯达克代码：APGE - 获取免费报告）内部人士 Carl Dambkowski 于 12 月 4 日星期四出售了 10,900 股该公司的股票。股票以平均价格 75.00 美元出售，总价值为 817,500.00 美元。出售后，该内部人士直接持有 271,108 股公司股票，价值 20,333,100 美元。这笔交易代表了他们持股比例的 3.87% 的减少。此次出售在提交给证券交易委员会的文件中披露，该文件可通过 SEC 网站获取。</p>
</div><ul>
<li>IPO watch 2024: Which new stocks will hit the market?</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年 IPO 观察：哪些新股票将上市？</li>
</ul>
</div><p>Carl Dambkowski also recently made the following trade(s):</p>
<div class="lb-trans"><p>Carl Dambkowski 最近还进行了以下交易：</p>
</div><ul>
<li>On Wednesday, November 5th, Carl Dambkowski sold 10,785 shares of Apogee Therapeutics stock. The stock was sold at an average price of $55.07, for a total value of $593,929.95.</li>
<li>On Wednesday, October 1st, Carl Dambkowski sold 5,110 shares of Apogee Therapeutics stock. The shares were sold at an average price of $39.80, for a total value of $203,378.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 11 月 5 日星期三，Carl Dambkowski 出售了 10,785 股 Apogee Therapeutics 的股票。股票以平均价格 55.07 美元出售，总价值为 593,929.95 美元。</li>
<li>在 10 月 1 日星期三，Carl Dambkowski 出售了 5,110 股 Apogee Therapeutics 的股票。股票以平均价格 39.80 美元出售，总价值为 203,378.00 美元。</li>
</ul>
</div><p>Get <strong>Apogee Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Apogee Therapeutics</strong> 的提醒：</p>
</div><h2>Apogee Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Apogee Therapeutics 价格表现</h2>
</div><p>Apogee Therapeutics stock traded up $1.25 during trading hours on Friday, hitting $76.75. The company had a trading volume of 733,690 shares, compared to its average volume of 715,559. Apogee Therapeutics Inc. has a fifty-two week low of $26.20 and a fifty-two week high of $77.09. The firm has a market capitalization of $5.24 billion, a P/E ratio of -17.52 and a beta of 1.41. The firm's fifty day moving average is $57.59 and its 200-day moving average is $45.43.</p>
<div class="lb-trans"><p>Apogee Therapeutics 的股票在周五的交易时段上涨了 1.25 美元，达到 76.75 美元。该公司的交易量为 733,690 股，而其平均交易量为 715,559 股。Apogee Therapeutics Inc.的 52 周低点为 26.20 美元，52 周高点为 77.09 美元。该公司的市值为 52.4 亿美元，市盈率为-17.52，贝塔值为 1.41。该公司的 50 日移动平均线为 57.59 美元，200 日移动平均线为 45.43 美元。</p>
</div><p>Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.03. Analysts anticipate that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.</p>
<div class="lb-trans"><p>Apogee Therapeutics（纳斯达克代码：APGE - 获取免费报告）最近于 11 月 10 日星期一发布了季度财报。该公司报告每股收益（EPS）为-1.11 美元，超出分析师一致预期的-1.14 美元，超出幅度为 0.03 美元。分析师预计 Apogee Therapeutics Inc.在当前年度的每股收益为-3.09 美元。</p>
</div><h2>Institutional Investors Weigh In On Apogee Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Apogee Therapeutics 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its holdings in shares of Apogee Therapeutics by 99.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company's stock worth $33,000 after purchasing an additional 383 shares during the period. ANTIPODES PARTNERS Ltd grew its position in Apogee Therapeutics by 41.2% during the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company's stock worth $33,000 after buying an additional 246 shares in the last quarter. Brooklyn Investment Group bought a new position in Apogee Therapeutics during the first quarter valued at about $42,000. AlphaQuest LLC acquired a new position in Apogee Therapeutics in the 1st quarter valued at approximately $43,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Apogee Therapeutics by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company's stock worth $77,000 after acquiring an additional 272 shares during the period. Institutional investors and hedge funds own 79.04% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对该股票的持有。Nisa Investment Advisors LLC 在第二季度将其在 Apogee Therapeutics 的持股增加了 99.2%。Nisa Investment Advisors LLC 现在拥有 769 股该公司的股票，价值 33,000 美元，此前在此期间购买了 383 股。ANTIPODES PARTNERS Ltd 在第三季度将其在 Apogee Therapeutics 的持股增加了 41.2%。ANTIPODES PARTNERS Ltd 现在拥有 843 股该公司的股票，价值 33,000 美元，此前在上个季度购买了 246 股。Brooklyn Investment Group 在第一季度购买了 Apogee Therapeutics 的新头寸，价值约 42,000 美元。AlphaQuest LLC 在第一季度获得了 Apogee Therapeutics 的新头寸，价值约 43,000 美元。最后，Mirae Asset Global Investments Co. Ltd.在第二季度将其在 Apogee Therapeutics 的持股增加了 18.0%。Mirae Asset Global Investments Co. Ltd.现在拥有 1,779 股该公司的股票，价值 77,000 美元，此前在此期间购买了 272 股。机构投资者和对冲基金持有该公司 79.04% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>APGE has been the subject of several recent research reports. BTIG Research reissued a &#34;buy&#34; rating and issued a $115.00 price target on shares of Apogee Therapeutics in a research note on Thursday, October 9th. Mizuho started coverage on shares of Apogee Therapeutics in a research report on Tuesday, October 21st. They issued an &#34;outperform&#34; rating and a $105.00 target price for the company. Royal Bank Of Canada increased their price target on shares of Apogee Therapeutics from $60.00 to $70.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, November 3rd. Wall Street Zen raised shares of Apogee Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 15th. Finally, Craig Hallum began coverage on shares of Apogee Therapeutics in a report on Monday, November 3rd. They issued a &#34;buy&#34; rating and a $109.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $98.38.</p>
<div class="lb-trans"><p>APGE 最近成为几份研究报告的主题。BTIG Research 在 10 月 9 日星期四重新发布了 “买入” 评级，并对 Apogee Therapeutics 的股票设定了 115.00 美元的目标价。瑞穗证券在 10 月 21 日星期二开始对 Apogee Therapeutics 的股票进行覆盖。他们对该公司发布了 “跑赢大盘” 评级和 105.00 美元的目标价。加拿大皇家银行在 11 月 3 日星期一将 Apogee Therapeutics 的股票目标价从 60.00 美元提高至 70.00 美元，并给予该股票 “跑赢大盘” 评级。Wall Street Zen 在 11 月 15 日星期六将 Apogee Therapeutics 的股票评级从 “卖出” 上调至 “持有”。最后，Craig Hallum 在 11 月 3 日星期一开始对 Apogee Therapeutics 的股票进行覆盖。他们对该公司发布了 “买入” 评级和 109.00 美元的目标价。一位投资分析师对该股票给予了强烈买入评级，七位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 98.38 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on APGE</strong></p>
<div class="lb-trans"><p><strong>查看我们对 APGE 的最新分析</strong></p>
</div><h2>Apogee Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Apogee Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.</p>
<div class="lb-trans"><p>Apogee Therapeutics, Inc.通过其子公司作为一家生物技术公司，开发用于治疗特应性皮炎（AD）、哮喘、慢性阻塞性肺病（COPD）及相关炎症和免疫学适应症的生物制剂。该公司主要开发 APG777，一种用于 AD 的皮下（SQ）延长半衰期单克隆抗体（mAb）；以及 APG808，一种用于 COPD 的 SQ 延长半衰期单克隆抗体。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Apogee Therapeutics</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Apogee Therapeutics 更好</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>Rocket Lab 的大反弹？分析师建议这次下跌是个机会</li>
<li>便士股票适合你的投资组合吗？</li>
<li>Meta 的 AI 时刻？新的 SAM 3 模型让华尔街变得乐观</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBHRQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=APGE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Apogee Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Apogee Therapeutics 吗？</h2>
</div><p>Before you consider Apogee Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Apogee Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Apogee Therapeutics 并不在名单上。</p>
</div><p>While Apogee Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Apogee Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Carl Dambkowski 出售了 10,900 股 Apogee Therapeutics（纳斯达克股票代码：APGE）的股票